Lineage Cell Therapeutics (LCTX) Return on Capital Employed (2011 - 2026)
Lineage Cell Therapeutics' (LCTX) quarterly Return on Capital Employed came in at 36.64% in Q1 2026, down 1519.0% year-on-year from 2.58% in Q1 2025, and up 10.2% quarter-over-quarter from 40.8% in Q4 2025.
Lineage Cell Therapeutics (LCTX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 36.64% for Q1 2026.
- On a quarterly basis, Return on Capital Employed fell 1519.0% year-over-year to 36.64% in Q1 2026; TTM through Mar 2026 was 36.64%, a 1519.0% decrease from a year earlier, with the FY2025 full-year figure at 36.07%, down 1301.0% from the prior year.
- Return on Capital Employed climbed to 36.64% in Q1 2026 per LCTX's latest filing, from 40.8% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 20.77% in Q4 2022 and bottomed at 43.52% in Q3 2025.
- The 5-year median for Return on Capital Employed is 28.32% (2024), against an average of 30.99%.
- Biggest YoY gain for Return on Capital Employed was 2576 bps in 2022; the steepest drop was 1824 bps in 2022.
- Year by year, Return on Capital Employed stood at 20.77% in 2022, then tumbled by 39 bps to 28.88% in 2023, then gained by 18 bps to 23.62% in 2024, then tumbled by 73 bps to 40.8% in 2025, then gained by 10 bps to 36.64% in 2026.
- Per Business Quant, the three latest LCTX Return on Capital Employed figures stand at 36.64% (Q1 2026), 40.8% (Q4 2025), and 43.52% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Lineage Cell Therapeutics | 267.08 Mn | 203.18 Mn | 1.73 Mn | -36.64% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -36.64% |
| Dec 31, 2025 | -40.80% |
| Sep 30, 2025 | -43.52% |
| Jun 30, 2025 | -38.93% |
| Mar 31, 2025 | -21.45% |
| Dec 31, 2024 | -23.62% |
| Sep 30, 2024 | -26.48% |
| Jun 30, 2024 | -28.32% |
| Mar 31, 2024 | -28.17% |
| Dec 31, 2023 | -28.88% |
| Sep 30, 2023 | -26.88% |
| Jun 30, 2023 | -24.44% |
| Mar 31, 2023 | -22.49% |
| Dec 31, 2022 | -20.77% |
| Sep 30, 2022 | -39.82% |
| Jun 30, 2022 | -39.70% |
| Mar 31, 2022 | -35.98% |
| Dec 31, 2021 | -46.53% |
| Sep 30, 2021 | -21.62% |
| Jun 30, 2021 | -21.46% |